Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

Table 3 Higher frequency of positive RA patients for IgG anti-alternative MAA-modified antigens than anti-HSA-MAA

Patient set^a	N^b	anti-Fib-MAA n (%)	p^c	anti-CFF(MAA)P n (%)	p^c	anti-HSA-MAA n (%)
All RA	178	32 (18.0)	0.002	34 (19.1)	0.001	13 (7.3)
Anti-CCP⁺	127	26 (20.5)	0.002	28 (22.0)	0.0008	9 (7.1)
Anti-CCP⁻	51	6 (11.8)	0.7	6 (11.8)	0.7	4 (7.8)

^aPatients with RA from the Barcelona collection were considered globally (All RA) and in the anti-CCP⁺ and anti-CCP⁻ subgroups
^bAbbreviations are as in Table 1 and Fib-MAA, MAA-modified fibrinogen; CFF(MAA)P, chimeric fibrin/filaggrin synthetic peptide containing MAA; HSA-MAA, MAA-modified human serum albumin
^cP values of the comparison with the anti-HSA-MAA percentage. Table 1 already presents anti-HSA-MAA results, but they are shown here for easy reference

ISSN: 1478-6362